Cancer Peptide Market Opportunity To Surpass US$ 18 Billion By 2030 Says Kuick ResearchDelhi, Nov. 25, 2024 (GLOBE NEWSWIRE) ...

VMT-alpha-NET is a somatostatin receptor type 2-targeted radiopharmaceutical therapy that can be radiolabeled with either 203Pb for patient selection and dosimetry assessments, or 212Pb for ...

Presenting initial results from the company-sponsored Phase 1/2a study of [212Pb]VMT-α-NET in patients with RPT-naïve neuroendocrine tumors at the upcoming 2024 North American Neuroendocrine Tumor ...

It provides services to 29 countries, working hand-in-hand with more than 31 pharmaceutical companies to develop and produce life-saving nuclear medicines, including those radiolabeled with 186 Re. By ...

A. N. Nesmeyanov Institute of Organoelement Compounds of Russian Academy of Sciences, 119991 st. Vavilova, 28, GSP-1, Moscow 119991, Russian Federation ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...